Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie av Seltorexant sammenlignet med Quetiapin XR som tilleggsterapi til antidepressiva hos voksne og eldre deltakere med alvorlig depressiv lidelse med søvnløshetssymptomer som har reagert utilstrekkelig på antidepressiv terapi

11. november 2026 oppdatert av: Janssen Research & Development, LLC

Dobbeltblind, randomisert, parallellgruppestudie med Quetiapin Extended Release som komparator for å evaluere effektiviteten og sikkerheten til Seltorexant 20 mg som tilleggsterapi til antidepressiva hos voksne og eldre pasienter med alvorlig depressiv lidelse med søvnløshetssymptomer som har reagert på inadekvate.

The purpose of this study is to assess the efficacy of seltorexant compared with quetiapine extended-release (XR) as adjunctive therapy to an antidepressant drug in treatment response in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).

Studieoversikt

Detaljert beskrivelse

Major depressive disorder (MDD) is a common, serious, recurrent disorder. Seltorexant (JNJ-42847922) is a potent and selective antagonist of the human orexin-2 receptor (OX2R) that is being developed for the adjunctive treatment of MDDIS. The hypothesis for this study is that seltorexant is superior to quetiapine XR in leading to a response after 26 weeks of treatment (greater than or equal to [>=] 50 percent [%] improvement on baseline Montgomery Asberg Depression Rating Scale [MADRS] total score), when administered as adjunctive treatment to an antidepressant in adult and elderly participants with MDDIS who have had an inadequate response to treatment with an SSRI/SNRI. The study will be conducted in 3 phases: a screening phase (up to 30 days), a double-blind (DB) treatment phase (26 weeks), and a post treatment follow-up phase (7 to 14 days after the end of DB treatment phase for all participants, and up to 196 days from baseline for participants who stop study treatment early). The total study duration for each participant will be approximately 32 weeks. Efficacy, safety, pharmacokinetics, and biomarkers will be assessed at specified time points during this study.

Studietype

Intervensjonell

Registrering (Faktiske)

757

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Buenos Aires, Argentina, 1058AAJ
        • CENydET - Centro Neurobiologico y de Stress Traumatico
      • Buenos Aires, Argentina, C1405BOA
        • FunDaMos
      • Buenos Aires, Argentina, 1199
        • Hospital Italiano
      • Ciudad Autonoma Buenos Aires, Argentina, C1428AQK
        • Hospital Fleni
      • Córdoba, Argentina, X5004AOA
        • Instituto Privado Kremer
      • Córdoba, Argentina, 5000
        • Fundacion Lennox
      • Córdoba, Argentina, X5006IKK
        • Centro Medico Luquez
      • La Plata, Argentina, Thanks
        • Clinica Privada de Salud Mental Santa Teresa de Ávila
      • La Plata, Argentina, 1902
        • CENPIA
      • Mendoza, Argentina, M5502AWY
        • CENAIN
      • San Miguel de Tucumán, Argentina, 4000
        • Clinica Mayo de UMCB
      • Bruges, Belgia, 8310
        • AZ Sint-Lucas
      • Sint-Niklaas, Belgia, 9100
        • AZ Nikolaas
      • Pleven, Bulgaria, 5800
        • Medical Center Medconsult-Pleven
      • Plovdiv, Bulgaria, 4028
        • MC 'Hipokrat - N', EOOD
      • Rousse, Bulgaria, 7003
        • Mental Health Center - Rousse
      • Sofia, Bulgaria, 1680
        • Medical Center Intermedica, OOD
      • Sofia, Bulgaria, 1113
        • Medical Center St. Naum
      • Sofia, Bulgaria, 1784
        • MC 'Synexus Sofia' EOOD
      • Stara Zagora, Bulgaria, 6003
        • UMHAT Prof. Dr. St. Kirkovich AD
      • Stara Zagora, Bulgaria, 6000
        • MC 'Synexus Sofia' EOOD
      • Tzarev Brod, Bulgaria, 9747
        • State Psychiatric Hospital - Tzarev Brod
      • Varna, Bulgaria, 9020
        • Diagnostic Consulting Center Mladost - M Varna
      • Veliko Tarnovo, Bulgaria, 5000
        • Mental Health Center - Veliko Tarnovo EOOD
    • Nova Scotia
      • Sydney, Nova Scotia, Canada, B1P 1E1
        • A.K. Munshi Medical Inc.
    • Ontario
      • Toronto, Ontario, Canada, M3J 2C5
        • Canadian Phase Onward
    • Quebec
      • Montreal, Quebec, Canada, H1M 1B1
        • Clinique Force Medic (GCP Trials)
    • Alabama
      • Birmingham, Alabama, Forente stater, 35233
        • University of Alabama at Birmingham
    • Arizona
      • Tucson, Arizona, Forente stater, 85712
        • SW Biomedical Research LLC
    • California
      • Culver City, California, Forente stater, 90230
        • Proscience Research Group
      • Encino, California, Forente stater, 91316
        • Pharmacology Research Institute
      • Garden Grove, California, Forente stater, 92845
        • Collaborative NeuroScience Network
      • Long Beach, California, Forente stater, 90806
        • Collaborative NeuroScience Network
      • Los Alamitos, California, Forente stater, 90720
        • Pharmacology Research Institute
      • Los Angeles, California, Forente stater, 90025
        • CalNeuro Research
      • Newport Beach, California, Forente stater, 92660
        • Pharmacology Research Institute
      • Orange, California, Forente stater, 92868
        • NRC Research Institute
      • Orange, California, Forente stater, 92868
        • Pacific Neuropsychiatric Specialists
      • Pico Rivera, California, Forente stater, 90660
        • CNRI-Los Angeles, LLC
      • Rancho Cucamonga, California, Forente stater, 91730
        • Prospective Research Innovations Inc
      • Redlands, California, Forente stater, 92374
        • Anderson Clinical Research
      • San Diego, California, Forente stater, 92103
        • University of California at San Diego
      • Santa Ana, California, Forente stater, 92705
        • CI Trials
      • Santa Ana, California, Forente stater, 91704
        • National Research Institute
      • Santee, California, Forente stater, 92071
        • CMB Clinical Trials
      • Sherman Oaks, California, Forente stater, 91403
        • Schuster Medical Research Institute
      • Upland, California, Forente stater, 91786
        • Pacific Clinical Research Medical Group
    • Connecticut
      • Hartford, Connecticut, Forente stater, 06102
        • Hartford Hospital
    • Florida
      • Doral, Florida, Forente stater, 33166
        • Moonshine Research Center, Inc
      • Hallandale, Florida, Forente stater, 33009
        • Velocity Clinical Research, Hallandale Beach
      • Hialeah, Florida, Forente stater, 33012
        • Indago Research & Health Center Inc
      • Hialeah, Florida, Forente stater, 33012
        • New Life Medical Research Center, Inc.
      • Hialeah, Florida, Forente stater, 33013
        • Amedica Research Institute Inc
      • Lakeland, Florida, Forente stater, 33803
        • Meridien Research
      • Miami, Florida, Forente stater, 33122
        • Premier Clinical Research
      • Miami, Florida, Forente stater, 33125
        • Global Medical Institutes
      • Miami, Florida, Forente stater, 33137
        • Miami Jewish Health System
      • Orlando, Florida, Forente stater, 32806
        • Synexus Research Orlando
      • Orlando, Florida, Forente stater, 23801
        • Clinical Neuroscience Solutions
      • Tampa, Florida, Forente stater, 33612
        • University of South Florida
      • The Villages, Florida, Forente stater, 32162
        • Compass Research LLC-Bioclinica Research
    • Georgia
      • Atlanta, Georgia, Forente stater, 30331
        • Atlanta Center for Medical Research
      • Atlanta, Georgia, Forente stater, 30328
        • Synexus Clinical Research US Inc
      • Decatur, Georgia, Forente stater, 30030
        • iResearch Atlanta LLC
      • Marietta, Georgia, Forente stater, 30060
        • Psych Atlanta, P.C.
    • Illinois
      • Chicago, Illinois, Forente stater, 60634
        • Chicago Research Center
      • Libertyville, Illinois, Forente stater, 60048
        • Capstone Clinical Research
      • Lisle, Illinois, Forente stater, 60532
        • Alexian Brothers Health System
      • Naperville, Illinois, Forente stater, 60563
        • Baber Research Group
      • Oakbrook Terrace, Illinois, Forente stater, 60618
        • Lemah Creek Clinical Research
    • Kansas
      • Wichita, Kansas, Forente stater, 67214
        • Ascension via Christi Research
    • Louisiana
      • New Orleans, Louisiana, Forente stater, 70115
        • Riverstar Research
    • Maryland
      • Baltimore, Maryland, Forente stater, 21208
        • Pharmasite Research, Inc.
    • Massachusetts
      • New Bedford, Massachusetts, Forente stater, 02740
        • BTC of New Bedford
      • Roslindale, Massachusetts, Forente stater, 02135
        • Boston Clinical Trials & Medical Research
    • Missouri
      • O'Fallon, Missouri, Forente stater, 63368
        • Psychiatric Care and Research Center (PCRC)
    • New Jersey
      • Toms River, New Jersey, Forente stater, 08755
        • Bio Behavioral Health
    • New York
      • Brooklyn, New York, Forente stater, 11235
        • SPRI Clinical Trials, LLC
      • New York, New York, Forente stater, 10128
        • The Medical Research Network, LLC
      • New York, New York, Forente stater, 10017
        • Fieve Clinical Research Inc
      • Rochester, New York, Forente stater, 14618 1609
        • Finger Lakes Clinical Research
      • Staten Island, New York, Forente stater, 10312
        • Richmond Behavioral Associates
    • North Carolina
      • Durham, North Carolina, Forente stater, 27701
        • Velocity Clinical Research, Inc.
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45219
        • University of Cincinnati, Dept of Psychiatry & Behavioral Neuroscience
      • Dayton, Ohio, Forente stater, 45417
        • Midwest Clinical Research Center
      • North Canton, Ohio, Forente stater, 44720
        • Neuro Behavioral Clinical Research
    • Oklahoma
      • Oklahoma City, Oklahoma, Forente stater, 73112
        • Sooner Clinical Research
      • Oklahoma City, Oklahoma, Forente stater, 73118
        • Paradigm Research Professionals, LLC
    • Pennsylvania
      • Pine Hill, Pennsylvania, Forente stater, 08021
        • Suburban Research Associates
      • Scranton, Pennsylvania, Forente stater, 18503
        • Global Medical Institutes
    • South Carolina
      • Mt. Pleasant, South Carolina, Forente stater, 29464
        • Coastal Carolina Research Center
    • Texas
      • Bellaire, Texas, Forente stater, 77401
        • West Houston Clinical Research Service
      • Fort Worth, Texas, Forente stater, 76104
        • North Texas Clinical Trials
      • Mansfield, Texas, Forente stater, 76054
        • Hawkins Psychiatry, PC
      • The Woodlands, Texas, Forente stater, 77381
        • Family Psychiatry of The Woodlands
      • Wichita Falls, Texas, Forente stater, 76309
        • Grayline Research Center
    • Utah
      • Clinton, Utah, Forente stater, 84015
        • Alpine Research Organization
      • Draper, Utah, Forente stater, 84020
        • Cedar Clinical Research
    • Virginia
      • Charlottesville, Virginia, Forente stater, 22903
        • University of Virginia
    • Washington
      • Bellevue, Washington, Forente stater, 98007
        • Northwest Clinical Research Center
      • Everett, Washington, Forente stater, 98201
        • Core Clinical Research
    • Wisconsin
      • Waukesha, Wisconsin, Forente stater, 53188
        • Cary J. Kohlenberg, MD, SC, dba, IPC Research.
      • Jelgava, Latvia, LV-3008
        • The Mental Hospital of Jelgava Ģintermuiža - Psychiatry
      • Liepāja, Latvia, LV-3401
        • L. Keruze Practice in Psychiatry
      • Outpatient Centre of Psychiatry, Latvia, LV-4601
        • Hospital of Rezekne
      • Riga, Latvia, LV-1002
        • Riga Centre of Psychiatry and Narcology
      • Kaunas, Litauen, 48259
        • Kaunas Silainiu Outpatient Clinic, Public Institution
      • Kaunas, Litauen, 53136
        • Republic Kaunas Hospital
      • Kaunas, Litauen, LT-44279
        • Romuvos Klinika, JSC
      • Kaunas, Litauen, LT-50009
        • Hospital of Lithuanian University of Health Sciences Kaunas Clinics
      • Vilnius, Litauen, 09112
        • Zirmunai Mental Health Center, Public Institution
      • Vilnius, Litauen, 10309
        • Vilnius Mental Health Center
      • Vilnius, Litauen, 10204
        • Antakalnis Psychiatric Consultation Centre, Public Institution
      • Šilutė, Litauen, 99176
        • Medical Center Puriena JSC
      • Ipoh, Malaysia, 30990
        • Hospital Raja Permaisuri Bainun
      • Johor Bahru, Malaysia, 81200
        • Hospital Permai
      • Pulau Pinang, Malaysia, 10990
        • Hospital Pulau Pinang
      • Seremban, Malaysia, 70300
        • Hospital Tuanku Jaafar
      • Bełchatów, Polen, 97-400
        • Gabinet Lekarski Psychiatryczny Ireneusz Kaczorowski
      • Bialystok, Polen, 15-464
        • Wlokiennicza MED Specjalistyczna Praktyka Lekarska dr n.med. Tomasz Markowski
      • Bydgoszcz, Polen, 85-080
        • Przychodnia Srodmiescie SP. z o.o.
      • Gdansk, Polen, 80 546
        • Centrum Badan Klinicznych PI House sp z o o
      • Lodz, Polen, 90-009
        • Specjalistyczna Indywidualna Praktyka Lekarska
      • Lodz, Polen, 90-368
        • CCBR - Lodz - PL
      • Lublin, Polen, 20-582
        • Specjalistyczna Praktyka Lekarska Marek Domanski
      • Poznan, Polen, 60-702
        • Synexus Polska Sp. z.o.o. Oddzial w Poznaniu
      • Warsaw, Polen, 01 737
        • Specjalistyczny Osrodek Medycyny Wieku Dojrzalego Sp z o.o.
      • Warsaw, Polen, 02 957
        • Instytut Psychiatrii I Neurologii
      • Engel's, Russland, 413124
        • Engels psychiatric hospital
      • Kemerovo, Russland, 650036
        • Kemerovo Regional Clinical Psychiatric Hospital
      • Lipetsk Region, Russland, 399313
        • GUZ Lipetsk Regional psychoneurological Hospital #1
      • Moscow, Russland, 105082
        • JSC Scientific Centre of Personalized Medicine
      • Moscow, Russland, 107076
        • FSI Moscow SRI of Psychiatry of Minzdravsocrazvitia
      • Moscow, Russland, 107076
        • Moscow Scientific Research Institute of Psychiatry
      • Omsk, Russland, 644070
        • Clinical Psychiatry Hospital n.a. N.N. Solodovnikov
      • Saint Petersburg, Russland, 192019
        • St-Petersburg Bekhterev Psychoneurological Research Institute
      • Tomsk, Russland, 634009
        • Klinika StoLet Ltd
      • Yekaterinburg, Russland, 620030
        • Sverdlov Regional Psychiatric Clinical Hospital
      • Belgrade, Serbia, 11000
        • University Clinical Center of Serbia
      • Belgrade, Serbia, 11000
        • General Hospital Euromedik
      • Belgrade, Serbia, 11000
        • University Clinical Hospital Center Dr Dragisa Misovic- Dedi
      • Belgrade, Serbia, 11000
        • General Hospital Acibadem Bel Medic
      • Belgrade, Serbia, 11000
        • Institute of Mental Health Serbia
      • Kovin, Serbia, 26220
        • Special Neuropsychiatric Hospital Kovin
      • Kragujevac, Serbia, 34000
        • University Clinical Center Kragujevac
      • Niš, Serbia, 18000
        • Clinical Center Nis
      • Novi Kneževac, Serbia, 23330
        • Specialized Hospital for Neuropsychiatric Diseases Sveti Vracevi
      • Banská Bystrica, Slovakia, 97401
        • Psychomed-Svatosavsky, s.r.o.
      • Bojnice, Slovakia, 97201
        • Nemocnica s poliklinikou Prievidza so sidlom v Bojniciach
      • Košice, Slovakia, 040 11
        • Epamed sro
      • Liptovský Mikuláš, Slovakia, 03123
        • Liptovska Nemocnica S Poliklinikou Mudr. Ivana Stodolu
      • Rimavská Sobota, Slovakia, 97901
        • Psychiatricka Ambulancia Psycholine S.R.O.
      • Trenčín, Slovakia, 91101
        • FN Trencin
      • Trenčín, Slovakia, 91108
        • Pro mente sana s.r.o.
      • Žilina, Slovakia, 1207
        • Fakultna nemocnica s poliklinikou v Ziline
      • Derby, Storbritannia, DE22 3LZ
        • Kingsway Hospital
      • Greater Manchester, Storbritannia, M15 6SX
        • Synexus
      • Harrogate, Storbritannia, HG1 2PW
        • Garden Valleys Resource Centre
      • London, Storbritannia, SE5 8EF
        • Kings College Hospital NHS Trust
      • Redruth, Storbritannia, TR15 2SP
        • Cornwall Partnership Foundation Trust
      • Brno, Tsjekkia, 60200
        • Psychiatricka ambulance Saint Anne s.r.o.
      • Hradec Králové, Tsjekkia, 500 09
        • NeuropsychiatrieHK, s.r.o.
      • Pilsen, Tsjekkia, 301 00
        • A Shine S R O
      • Prague, Tsjekkia, 100 00
        • Clintrial s r o
      • Prague, Tsjekkia, 160 00
        • NeuropsychiatrieHK, s.r.o.
      • Prague, Tsjekkia, 10000
        • AD71 s.r.o.
      • Prague, Tsjekkia, 186 00
        • Institut Neuropsychiatricke pece
      • Hlevakha, Ukraina, 8631
        • MNCE of Kyiv RC Regional Psychiatric and Narcological Medical Association
      • Kharkiv, Ukraina, 61068
        • Mnpe of Kharkiv Regional Council 'Regional Clinical Psychiatric Hospital #3'
      • Kyiv, Ukraina, 04080
        • Kyiv Territorial Medical Incorporation 'Psychiatry'
      • Kyiv, Ukraina, 1030
        • Railway Clinical Hospital #1 of Kiev Railway station of DTGO 'South-Western Railway'
      • Kyiv, Ukraina, 1034
        • Medical Center Health and Happy
      • Nove, Ukraina, 25491
        • Mnpe 'Regional Clinical Psychiatric Hospital of Kirovohrad Regional Council'
      • Ternopil, Ukraina, 46020
        • Ternopil RCCPH Depts of Psychiatry #2 (m) & Psychiatry #4 (f) Ternopil I.Ya. Gorbachevskyi SMU
      • Zaporizhzhya, Ukraina, 69600
        • Zaporizhzhia Regional Clinical Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 74 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Meet diagnostic and statistical manual of mental disorders-5th edition (DSM-5) diagnostic criteria for major depressive disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the structured clinical interview for DSM-5 Axis I disorders-clinical trials version (SCID-CT) diagnosed with first depressive episode prior to age 60. The length of the current depressive episode must be less than or equal to (<=) 24 months
  • Have had an inadequate response to at least 1 but no more than 2 antidepressants, administered at an adequate dose and duration in the current episode of depression. The current antidepressant cannot be the first antidepressant treatment for the first lifetime episode of depression. An inadequate response is defined as less than (<) 50 percent (%) reduction but with some improvement (that is, improvement greater than [>] 0%) in depressive symptom severity with residual symptoms present other than insomnia, and overall good tolerability, as assessed by the Massachusetts General Hospital-Antidepressant Treatment Response Questionnaire (MGH-ATRQ)
  • Is receiving and tolerating well any one of the following selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) for depressive symptoms at screening, in any formulation and available in the participating country: citalopram, duloxetine, escitalopram, fluvoxamine, fluoxetine, milnacipran, levomilnacipran, paroxetine, sertraline, venlafaxine, desvenlafaxine, vilazodone, or vortioxetine at a stable dose (at or above therapeutic dose level) for at least 6 weeks, and for no greater than 18 months in the current episode
  • Have a hamilton depression rating scale (HDRS)-17 total score greater than or equal to (>=) 20 at the first screening interview, must not demonstrate a clinically significant improvement (that is, an improvement of > 20% on their HDRS-17 total score) from the first to the second independent HDRS-17 rating, and must have a HDRS-17 total score >18 at the second screening interview
  • Have a patient version insomnia severity index (ISI) total score >= 15 as well as a clinician version of the ISI total score >= 15 at the second screening visit
  • Body mass index (BMI) between 18 and 40 kilogram per meter square (kg/m^2), inclusive (BMI=weight/height^2)
  • Participant must be medically stable on the basis of the following: physical examination, vital signs (including blood pressure), and 12-lead electrocardiogram (ECG) performed at screening and baseline

Exclusion Criteria:

  • Has a recent (last 3 months) history of, or current signs and symptoms of, severe renal insufficiency (creatinine clearance [CrCl] less than [<] 30 milliliter per minute [mL/min]); clinically significant or unstable cardiovascular, respiratory, gastrointestinal, neurologic, hematologic, rheumatologic, immunologic or endocrine disorders. uncontrolled Type 1 or Type 2 diabetes mellitus
  • Has a history of treatment-resistant MDD, defined as a lack of response to 2 or more adequate antidepressant treatments in the current episode, as indicated by no or minimal (<25% improvement in symptoms) when treated with an antidepressant of adequate dose (per MGH-ATRQ) and duration (at least 6 weeks)
  • Has history or current diagnosis of a psychotic disorder, bipolar disorder, intellectual disability, autism spectrum disorder, borderline personality disorder, somatoform disorders
  • Has a history of moderate to severe substance use disorder including alcohol use disorder according to DSM-5 criteria within 6 months before screening
  • Has any significant primary sleep disorder, including but not limited to obstructive sleep apnea, restless leg syndrome, or parasomnias. Participants with insomnia disorder are allowed

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Seltorexant

Adult participants will receive seltorexant once daily from Day 1-7 and together with matching placebo from Day 8 till Day 182. Elderly participants will receive seltorexant once daily from Day 1-3 and together with matching placebo from Day 4 till Day 182.

Participants will receive seltorexant over-encapsulated tablet orally.

Participants will receive placebo over-encapsulated tablet matching to seltorexant orally.

Aktiv komparator: Quetiapine Extended-Release (XR)

Adult participants will receive quetiapine XR once daily from Day 1-2, followed by an increase in dose from Day 3-7, and from Day 8-14 together with matching placebo. After Day 14, quetiapine XR twice daily from Day 14 till Day 182. Elderly participants will receive quetiapine XR once daily from Day 1-3 and twice from Day 4-7, followed by an increase in dose once daily from Day 8-14 together with matching placebo. After Day 14 till Day 182, quetiapine XR will be adjusted by investigator based on the participant's clinical response and tolerability.

Participants will receive quetiapine XR capsule orally.

Participants will receive placebo capsule matching to quetiapine XR orally.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of Participants Who Achieved Response (Greater Than or Equal to [>=50] Percent Improvement in Montgomery-Asberg Depression Rating Scale [MADRS] Total Score From Baseline) at Week 26
Tidsramme: Week 26

Percentage of participants who achieved response at Week 26 was reported. Responders were defined as participants with >= 50 percent (%) improvement in the MADRS total score from baseline. MADRS was a clinician-administered scale designed to measure depression severity and detected changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.

Week 26

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change From Baseline to Week 26 in Weight
Tidsramme: Baseline (Day 1) and Week 26

Change from baseline to Week 26 in weight was reported.

Baseline (Day 1) and Week 26
Time to Potentially Treatment Related Discontinuation of Study Drug
Tidsramme: From first dose of study drug (Day 1) up to Week 30

Time to potentially treatment related discontinuation of study drug was reported. Time to discontinuation of study drug was defined as the number of days from the first dose of study drug to the last dose of study drug. Potentially treatment related discontinuation of study drug was defined as all study drug discontinuations excluding the potentially non-treatment related discontinuations (such as, loss of insurance for antidepressant therapy, movement/travel out of the area, change of work-schedule being unable to accommodate visit schedule, family circumstances, site terminated by sponsor, study terminated by sponsor). Kaplan-Meier estimate was used.

From first dose of study drug (Day 1) up to Week 30
Change From Baseline to Week 26 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Tidsramme: Baseline (Day 1) and Week 26

Change from baseline to Week 26 in MADRS total score were reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.

Baseline (Day 1) and Week 26
Change From Baseline to Week 26 in MADRS-6 Total Score
Tidsramme: Baseline (Day 1) and Week 26

Change from baseline to Week 26 in MADRS-6 total score was reported. The MADRS-6 scale was a clinician-administered questionnaire used to measure the severity of MDD symptoms. The MADRS-6 scale was a subset of the MADRS-10 scale, comprised of the following individual questionnaire items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), the overall score ranged from 0 to 36, higher scores represented a more severe condition.

Baseline (Day 1) and Week 26
Change From Baseline to Week 26 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score
Tidsramme: Baseline (Day 1) and Week 26

The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. MADRS-WOSI was defined as the full MADRS without the sleep item. The MADRS-WOSI scale consisted of 9 items (apparent sadness, reported sadness, inner tension, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS-WOSI total score was the sum of scores from individual question items, which ranged from 0 to 54, higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement.

Baseline (Day 1) and Week 26
Change From Baseline to Week 26 in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score
Tidsramme: Baseline (Day 1) and Week 26

Change from baseline to Week 26 in PHQ-9 total score was reported. The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the diagnostic and statistical manual of mental disorders-5th edition (DSM-5) major depressive disorder (MDD) criteria. Each item was rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. Negative changes in PHQ-9 total score indicated improvement.

Baseline (Day 1) and Week 26
Percentage of Participants With MADRS Total Score Less Than or Equal to (<=) 12 at Week 26
Tidsramme: Week 26

Percentage of participants with MADRS total score <=12 at Week 26 was reported. A participant was defined as a remitter at a given time point if the MADRS total score was <=12 at that time point. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.

Week 26
Percentage of Participants With a >=50 Percent Improvement in MADRS Total Score and MADRS <=18 at Week 26
Tidsramme: Week 26

Percentage of participants with a >=50 percent improvement in MADRS total score and MADRS <=18 at Week 26 was reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.

Week 26
Percentage of Participants With >=7 Percent Weight Increase From Baseline at Week 26
Tidsramme: Week 26

Percentage of participants with >=7 percent weight increase from baseline at Week 26 was reported.

Week 26

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

15. september 2020

Primær fullføring (Faktiske)

3. oktober 2023

Studiet fullført (Faktiske)

3. oktober 2023

Datoer for studieregistrering

Først innsendt

13. august 2020

Først innsendt som oppfylte QC-kriteriene

13. august 2020

Først lagt ut (Faktiske)

14. august 2020

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

13. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

11. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • CR108810
  • 42847922MDD3005 (Annen identifikator: Janssen Research & Development, LLC)
  • 2020-000341-14 (EudraCT-nummer)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical- trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere